Safety Study and Preliminary Efficacy of Infusion Haploidentical Mesenchymal Stem Cells Derived From Bone Marrow for Treating Recessive Dystrophic Epidermolysis Bullosa

Phase I / II pilot clinical trial, to evaluate the safety and preliminary efficacy of the systemic infusion of mesenchymal stem cells derived from bone marrow (BM-MSCs) from a haploidentical donor to improve the healing process and / or the mucocutaneous fragility phenotype associated with EBDR.

Study Overview

• Status: Unknown
• Conditions: Epidermolysis Bullosa Dystrophica, Recessive
• Intervention / Treatment: Biological: mesenchymal stem cells derived from bone marrow (BM-MSCs)

Detailed Description

The Main Objective is to evaluate the safety and therapeutic efficacy of haploidentical MSCs derived from bone marrow administered by intravenous injection for the treatment of patients with RDBS. The assessment of the symptomatic improvement of the treated patients will be made regarding the baseline situation and the response to treatment at the biochemical, histological and molecular level.

Secondary Objectives:

Describe the clinical and molecular phenotype of the mucocutaneous involvement of patients, including the characterization of the mutations responsible for the disease.

Study drug: Allogenic mesenchymal cells (haploidentical) derived from bone marrow and expanded.

Method of administration: Systemic / Intravenous Administration dose: 2-3x10e6 BM-MSC / Kg. Weekly dose for three consecutive weeks

Follow-up period: 12 months after the infusion. However, patients will be monitored outside the clinical trial over a 5-year period

• Study Type: Interventional
• Enrollment (Actual): 9
• Phase: Phase 2; Phase 1

Contacts and Locations

Study Locations

• Spain
  • Madrid, Spain, 28046
    • Hospital Universitario La Paz

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 1 year to 18 years (Child, Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

1. Male and female patients ≥ 12 months and ≤ 18 years of age at the time of inclusion in the study.
2. Patients with a clinical, molecular and genetic diagnosis of EBDR.
3. Patients with presence of the NC-1 domain of type VII collagen, in skin biopsies and/or Western-Blot, detected with a battery of specific antibodies.
4. Patients with a haploidentical donor.
5. Subjects with a severity score> 20 according to "The Birmingham Epidermolysis Bullosa Severity Score".
6. Minor subjects whose representative / legal guardian has voluntarily signed the informed consent before the first intervention of the study.
7. In the case of mature minors (12-17 years of age), in addition to the consent signed by the legal guardian, the consent of the minor will be obtained.
8. Women with reproductive capacity must have a negative pregnancy test at the time of inclusion and must agree to use highly effective contraceptive methods (diaphragms plus spermicide or male condom plus spermicide, oral contraceptive combined with a second method contraceptive implant, contraceptive injectable, permanent intrauterine device, sexual abstinence or partner with vasectomy) during their participation in the study until 30 days after the last visit.
9. Males should agree to use a double-barrier contraceptive method (condom plus spermicide or diaphragm plus spermicide) during their participation in the study and up to 30 days after the last dose of the study drug, or the male patient or his Female partners must be surgically sterilized or the female partner must be postmenopausal.
10. The patient must be able to attend all study visits and comply with all study procedures.

Exclusion Criteria:

1. Subjects who for medical reasons can not be moved to the University Hospital La Paz in Madrid.
2. Subjects who have received immunotherapy including oral corticosteroids (> 15 mg / day) for more than 1 week (excluding inhaled and ophthalmic preparations) or chemotherapy 8 days prior to inclusion in the study. The inclusion of the patient is understood from the signing of the informed consent.
3. Subjects with a known allergy to any of the components of the investigational product (including penicillin and streptomycin), or who can not receive treatment with antihistamines and/or corticosteroids.
4. Subjects with signs of active systemic infection at the time of inclusion in the study. In any case, according to the researcher's criteria, the patient can be reevaluated for inclusion in the study after improvement of the infectious pathology.
5. Subjects with a history or signs of malignancy, including cutaneous squamous cell carcinoma.
6. Subjects with circulating anti-C7 antibodies and anti-C7 antibodies deposited in the dermo-epidermal junction detected in skin biopsies by indirect immunofluorescence.
7. Pregnant women at the time of inclusion or women of childbearing age who do not practice abstinence or employ acceptable means of contraception, as determined by the investigator during the trial.
8. Biochemical abnormalities at the time of inclusion: albumin <2.5 g / dL, Hemoglobin <7.5 g / dL.
9. Subjects to whom other investigational drugs have been administered in the 90 days prior to the treatment phase.
10. Subjects who are unable to understand the information sheet and unable to sign the informed consent.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Haploidentical MSCs derived from bone marrow; Haploidentical MSCs derived from bone marrow administered by intravenous injection with a dose of 2-3x106 cells / Kg	Biological: mesenchymal stem cells derived from bone marrow (BM-MSCs); Procedure: Haploidentical MSCs derived from bone marrow administered by intravenous injection with a dose of 2-3x106 cells / Kg

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Safety evaluation: Incidence of Treatment-Emergent Adverse Events as assessed by protocol.	To evaluate the safety of haploidentical MSCs derived from bone marrow administered by intravenous injection with a dose of 2-3x106 cells / Kg in 3 infusions separated by 21 days each for the treatment of patients with RDEB: All adverse events will be registered for 1 year from first infusion of cells as assessed by grade: mild, moderate or severe (according to protocol)	1 year after infusion

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Cutaneous mechanical resistance	Cutaneous mechanical resistance measured using a negative pressure cutaneous suction device from Electronic Diversities (NP-2 model).	2 year after infusion
Skin surface affected	Percentage of skin surface affected in patients with RDEB	2 year after infusion
Number of blisters	Quantification of the number of blisters in patient with RDEB	2 year after infusion
Non-specific general markers of systemic inflammation: white blood cell count	Biomarkers evaluated are white blood cell count (109/L)	2 year after infusion
Non-specific general markers of systemic inflammation: Negative acute phase reactant (albumin)	Biomarkers evaluated are negative acute phase reactants: albumin (g/dl)	2 year after infusion
Non-specific general markers of systemic inflammation: Negative acute phase reactants (pre-albumin, transferrin and retinol-binding protein)	Biomarkers evaluated are negative acute phase reactants: pre-albumin, transferrin, and retinol-binding protein (mg/dl)	2 year after infusion
Non-specific general markers of systemic inflammation: Positive acute phase reactants (c-reactive protein and fibrinogen)	Biomarkers evaluated are positive acute phase reactants: C reactive protein and fibrinogen (mg/dl)	2 year after infusion
Non-specific general markers of systemic inflammation: Positive acute phase reactants (ferritin)	Biomarkers evaluated are positive acute phase reactants: ferritin (ng/ml)	2 year after infusion
Severity index according to "The Birmingham Epidermolysis Bullosa Severity Score" before and after treatment	The Birmingham Epidermolysis Bullosa Severity Score evaluated the severity of disease before and after treatment. Eleven items were scored: area of damaged skin, involvement of nails, mouth, eyes, larynx and oesophagus, scarring of hands, skin cancer, chronic wounds, alopecia and nutritional compromise (giving a maximum score of 100, where 0 = better outcome and 100 = worse outcome)	2 year after infusion
Severity index according to "The Epidermolysis Bullosa Disease Activity and Scarring Index (EBDASI) before and after treatment	The Epidermolysis Bullosa Disease Activity and Scarring Index (EBDASI) used to classify patients according to disease severity and clinical response in three types: mild, moderate and severe (obtained by the analysis of 12 skin sites in addition to the scalp, mucous membranes, nails and other epithelized surfaces - total activity (of 276) and damage (of 230) combine to give an overall score of 506; where 0 = better outcome and 506 = worse outcome).	2 year after infusion
Expression of Collagen VII (C7) in skin biopsy	Expression of Collagen VII (C7) in skin biopsy will be analyzed by immunofluorescence with antibodies specific for the NC1 domain of collagen VII.	2 year after infusion
Analysis of anchoring fibrils	Analysis of anchoring fibrils by electron microscopy in skin biopsy after treatment	2 year after infusion
Variation of pain respect to baseline status: Visual Analog Scale	Variation of pain with respect to baseline that will be assessed using the Visual Analogy Scale (VAS) in all visits after the first infusion, used different type of VAS scale depends on age of subject. Range was 1 to 10, where 10 are considered a worse outcome.	2 year after infusion
Modification in itching perceived	Assessment of the change in the itching perceived respect baseline status will be assessed by Leuven Itch Scale or Itch Man Scale, depends on the age of the subject. These scales are the instrument to evaluate itching perceived in patients with pruritus origin different. There subscale in 6 domains: frequency, duration, severity, distress, impact, and area: Itch frequency score: scale from 0 to 100. (Maximum score 100, itching all the time - is worse outcome) Itch severity score: scale from 0 to 100 (Maximum score 100, maximum severity =worse outcome) Itch distress score: scale from 0 to 100 (Maximum score 100, maximum distress = worse outcome) Itch consequences score: scale from 0 to 100 (Maximum score 100, maximum consequences = worse outcome) Itch Surface area score: Scale from 0 to 100 (Maximum score is 100, the entire body = worse outcome).	2 year after infusion
Change in quality of life of patient: European Quality of Life-5 Dimensions-5 level (EUROQL-5D)	Assessment of the change in quality of life: survey of specific assessment of the quality of life (European Quality of Life-5 Dimensions-5 level; EUROQL-5D). The descriptive system comprises five dimensions: mobility, self-care, habitual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels of gravity, where a value of 1 is better outcome and 3 is worse outcome. Also, there are a 2nd part included a VAS scale, where 0 = worse outcome and 100 =better outcome.	2 year after infusion
Evaluation of circulating anti-C7 antibodies	Analysis of circulating anti-C7 antibodies determined by ELISA before and after treatment.	2 year after infusion
Change in general condition of the patient	Evaluation of the changes produced in the patient before and after the study treatment, assessing according to the set of tests performed on the patient during the same; indicating it through a Likert scale, from 1-4, where 4 is the most serious evaluation and 1 is the slightest.	2 year after infusion

Collaborators and Investigators

• Sponsor: Instituto de Investigación Hospital Universitario La Paz
• Collaborators: Instituto de Salud Carlos III; Universidad Carlos III Madrid (TERMeG); St John's Institute of Dermatology Kings College London; DEBRA; CIBER Enfermedades raras

Study record dates

Study Major Dates

• Study Start (Actual): May 17, 2018
• Primary Completion (Anticipated): March 1, 2021
• Study Completion (Anticipated): March 1, 2021

Study Registration Dates

• First Submitted: August 6, 2019
• First Submitted That Met QC Criteria: November 5, 2019
• First Posted (Actual): November 6, 2019

Study Record Updates

• Last Update Posted (Actual): November 8, 2019
• Last Update Submitted That Met QC Criteria: November 7, 2019
• Last Verified: April 1, 2019

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Skin Diseases; Congenital Abnormalities; Genetic Diseases, Inborn; Connective Tissue Diseases; Skin Diseases, Genetic; Skin Diseases, Vesiculobullous; Skin Abnormalities; Collagen Diseases; Epidermolysis Bullosa; Epidermolysis Bullosa Dystrophica
• Other Study ID Numbers: MesenSistem-EB

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No